Petros Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Petros Pharmaceuticals has been growing earnings at an average annual rate of 9.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 32.2% per year.

Belangrijke informatie

9.6%

Groei van de winst

71.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	-32.2%
Rendement op eigen vermogen	-76.8%
Nettomarge	-501.0%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Aug 15

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Jul 28

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Dec 07

Opbrengsten en kosten

Hoe Petros Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:PTPI Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	4	-21	10	3
31 Mar 24	5	-20	10	4
31 Dec 23	6	-14	9	2
30 Sep 23	7	-13	9	2
30 Jun 23	4	-22	9	2
31 Mar 23	6	-21	10	2
31 Dec 22	6	-20	12	2
30 Sep 22	4	-24	13	3
30 Jun 22	8	-12	15	2
31 Mar 22	6	-12	16	2
31 Dec 21	8	-9	16	2
30 Sep 21	12	-6	15	1
30 Jun 21	13	-8	15	1
31 Mar 21	12	-11	15	0
31 Dec 20	10	-21	16	0
30 Sep 20	9	-24	16	0
30 Jun 20	10	-29	19	0
31 Mar 20	12	-32	20	0
31 Dec 19	16	-33	20	0
31 Dec 18	14	-32	11	0

Kwaliteitswinsten: PTPI is currently unprofitable.

Groeiende winstmarge: PTPI is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: PTPI is unprofitable, but has reduced losses over the past 5 years at a rate of 9.6% per year.

Versnelling van de groei: Unable to compare PTPI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: PTPI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).

Rendement op eigen vermogen

Hoge ROE: PTPI has a negative Return on Equity (-76.81%), as it is currently unprofitable.

Petros Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

Recent updates

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Petros Pharmaceuticals, Inc. Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Petros Pharmaceuticals, Inc. Announces Results of First of Series of Pivotal Studies Aimed at Facilitating FDA-Approved OTC Access of STENDRA (Avanafil) for Consumers

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) (Avanafil)

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Petros Pharmaceuticals, Inc. announced delayed 10-Q filing

Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021)

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021)

Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA

Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020)

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil)

Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding

Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million.

Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding

Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020)

Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020)

New 90-day low: US$3.22

Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

Petros Pharmaceuticals, Inc. Announces Executive Changes

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden